An object of the present invention is to provide a technique capable of improving the cell binding properties of a liposome, an exosome, or a lipid nanoparticle, and a lipid compound having a group represented by Formula (1) is provided. (1):
An object of the present invention is to provide a technique capable of improving the cell binding properties of a liposome, an exosome, or a lipid nanoparticle, and a lipid compound having a group represented by Formula (1) is provided. (1):
XaXb—(X1)p(X2)q—(X3X4)r—(O—Z)S—
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
The present invention provides novel and effective cancer immunotherapeutic agents that exhibit therapeutic effects on intractable cancers, particularly cancers for which immune checkpoint inhibitor(s) monotherapy or combined use thereof with other drug(s) is ineffective. Specifically, a cancer therapeutic agent containing an immune checkpoint inhibitor, interleukin-18 (IL-18), and a T cell growth factor (e.g., interleukin-2 (IL-2)) in combination is provided.
The purpose of the present invention is to provide a composition for preventing or treating a chemosensory disorder. The present invention provides a composition for preventing or treating a chemosensory disorder, the composition including lactic acid bacteria. The chemosensory disorder may be a chemosensory disorder that occurs after SARS-CoV-2 virus infection. The present invention is advantageous in that lactic acid bacteria can be used as a functional ingredient that imparts a preventive or therapeutic effect for a chemosensory disorder, and in that pharmaceuticals or foodstuffs that are safe for mammals, including humans, can be provided.
It has been suggested that IL-18 is involved in interstitial lung diseases, but there have been no effective therapeutic drugs. It has been shown that pulmonary fibrosis is suppressed biochemically and pathologically by administering an anti-active IL-18 antibody that recognizes a neoepitope of active IL-18 to a bleomycin-induced interstitial lung disease mouse model. No therapeutic effect was confirmed with antibodies that recognize regions other than IL-18 BP and neoepitopes of IL-18. The anti-active IL-18 antibody is an effective therapeutic drug against interstitial lung diseases, particularly progressive interstitial lung diseases, for which an effective therapeutic drug has not existed.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
5.
PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASE INDUCED BY PARASITE
NATIONAL UNIVERSITY CORPORATION HOKKAIDO HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
NAGASAKI UNIVERSITY (Japan)
MITOCHONDRIA LABORATORY (Japan)
Inventor
Suganuma, Keisuke
Kita, Kiyoshi
Yamamoto, Masakazu
Abstract
Provided are a prophylactic or therapeutic agent for a disease induced by a parasite, the agent being capable of reducing the dosage of ascofuranone or glycerol, a pharmaceutical, a food, a beverage, a feed and a pharmaceutical composition. This prophylactic or therapeutic agent for a disease induced by a parasite comprises, as an active ingredient, ascofuranone-producing fungal cells that contain ascofuranone produced by per se.
A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
PROTEIN AGGREGATE DECOMPOSITION PROMOTING COMPOSITION AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH PROTEIN AGGREGATE FORMATION
The present invention addresses the problem of providing: a protein aggregate decomposition promoting composition; and a pharmaceutical composition for prevention or treatment of neurodegenerative diseases associated with protein aggregate formation. The abovementioned problem is solved by a compound represented by general formula (I).
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The present invention provides a compound represented by formula (I) [each symbol in formula (I) is as described in the accompanying description], or a salt thereof.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Foundation for Biomedical Research and Innovation at Kobe (Japan)
National Institutes for Quantum Science and Technology (Japan)
Inventor
Tanaka, Yoshimasa
Sakuraba, Shun
Abstract
A novel interleukin-18 (IL-18) variant and a pharmaceutical composition using the same, which relates to a human IL-18 variant including (i) mutations of cysteine at positions 38, 68, 76, and 127 into serine and (ii) mutations of glutamic acid at position 6 and lysine at position 53 into alanine relative to an amino acid sequence of wild-type human IL-18, where the variant further includes (iii) at least one additional mutation, and a pharmaceutical composition containing the human IL-18 variant.
The present invention provides: a method for producing umbilical cord-derived mesenchymal cells that highly express a vascular endothelial growth factor, the method comprising a step for culturing an umbilical cord-derived mesenchymal stem cell on a collagen gel; and a pharmaceutical composition that is for treating pulmonary diseases, and that contains, as an active ingredient, the produced umbilical cord-derived mesenchymal cells that highly express a vascular endothelial growth factor.
A composition having cell-derived physiological activity is provided. An osteogenic composition includes a treated product obtained by treating megakaryocytes or treating a culture thereof.
A61K 31/405 - Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A sheet-shaped cell culture for covering a cut surface of a pancreas, the cut surface of the pancreas includes cut surfaces of a pancreatic parenchyma and a pancreatic duct, and is connected to an intestinal wall of a small intestine in a liquid-tight manner via the sheet-shaped cell culture. A method for preventing or treating pancreatic fistula includes a step of covering, using a sheet-shaped cell culture, a cut surface of a pancreas that includes cut surfaces of a pancreatic parenchyma and a pancreatic duct, and a step of connecting the cut surface of the pancreas to an intestinal wall of a small intestine in a liquid-tight manner via the sheet-shaped cell culture.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
NAGASAKI UNIVERSITY (Japan)
Inventor
Yamasaki, Kazuhiko
Tateno, Hiroaki
Shimizu, Hiroki
Morita, Kouichi
Ngwe Tun, Mya Myat
Abstract
Provided is a lectin that is useful for treatment and/or diagnosis of infectious diseases from viruses such as SARS-CoV-2, the lectin binding strongly to N-linked sugar chain in S protein, and being producible in a simple manner and at a low cost. The present invention is a pharmaceutical composition for treatment or diagnosis of virus infectious diseases, the composition containing an active peptide that binds to a virus to inhibit the infection therewith. The active peptide is selected from: Pholiota squarrosa lectin (PhoSL), which is a lectin that binds to an α1-6 fucose sugar chain and has amino acid sequences represented by SEQ ID NOs: 1-4; and a mutant peptide which has PhoSL amino acid sequences represented by SEQ ID NOs: 1-4 with a modification introduced to each of said sequences, the modification being selected from substitution, deletion, insertion and addition of 1 to 4 amino acids.
Provided is a therapeutic drug for fungal infection, the drug containing human γδT cells as an active ingredient. The therapeutic agent for fungal infection has no adverse effects and tends not to be affected by drug resistance.
Provided—as a therapeutic agent for pulmonary fibrosis and a therapeutic method for pulmonary fibrosis, for which therapeutic effects can be expected—is a therapeutic agent for pulmonary fibrosis for which an active ingredient is γδ T-cells.
A cover (2) comprises: a cover member (10) which covers a part of the outer peripheral surface of a rigid endoscope (50) in the circumferential direction, in which one or a plurality of grooves (12, 14) extending in parallel with each other along the longitudinal direction of the rigid endoscope (50) are formed, and which has flexibility; and tubular members (40, 42) which are fitted into the grooves (12, 14) of the cover member (10) and in which cleaning fluid to be supplied from the proximal end side of the rigid endoscope (50) to an observation window portion of the rigid endoscope (50) is caused to flow. A discharge portion (20), in which a plurality of discharge ports (22, 24) are formed, is provided with a branch portion (27) that causes the cleaning fluid supplied from the tubular members (40, 42) to branch off and to be discharged from the respective discharge ports (22, 24) toward the observation window portion.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with cooling or rinsing arrangements
17.
SUPPORT FOR DIAGNOSIS OF NEUROPSYCHIATRIC SLE BY MEANS OF HEAD MRI
The present invention provides a method for obtaining an index for diagnosing whether a subject is an SLE patient or an NPSLE patient, the method including: (1) a step for preparing head MRI images of SLE patients and NPSLE patients; (2) a step for gradually changing the color tone of the MRI images; (3) a step for detecting and counting white connected components and black connected components that appear as the color tone is changed; (4) a step for obtaining scatter plots of the appearance and disappearance times of the individual white connected components and black connected components on the basis of the results in step (3); (5) a step for verifying whether or not there is any significant difference between individual image features of the SLE patients and the NPSLE patients, obtained from the scatter plots; and (6) a step for identifying an image feature with which a significant difference is observed as the index.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01N 33/66 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
18.
PHARMACEUTICAL COMPOSITION FOR SUPPRESSING ORGAN FIBROSIS
The present invention provides a pharmaceutical composition for suppressing organ fibrosis, characterized by having an angiotensin II receptor antagonist as an active ingredient, and being administered at a dosage of 0.2 times or less the dosage as an antihypertensive drug per day.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
19.
THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19)
The present invention provides a therapeutic and/or preventive agent for coronavirus disease 2019 (COVID-19) comprising 5-aminolevulinic acid (ALA) or its derivative or a salt thereof and provides a method for treating and/or preventing coronavirus disease 2019 (COVID-19) using the therapeutic and/or preventive agent.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
A61P 11/00 - Drugs for disorders of the respiratory system
This nucleic acid transport carrier contains: a polylysine dendrimer with phenylalanine bonded to an end thereof; and biodegradable cationic molecules. The nucleic acid transport carrier contains: a polylysine dendrimer with phenylalanine bonded to an end thereof; and a polylysine dendrimer or a polylysine dendrimer with arginine bonded to an end thereof. The nucleic acid transport carrier contains a polylysine dendrimer with arginine bonded to an end thereof via phenylalanine. The nucleic acid transport carrier contains an integrated dendrimer in which a polylysine dendron with phenylalanine bonded to an end thereof and a polylysine dendron with arginine bonded to an end thereof are bonded to each other.
LYMPHOCYTE FUNCTION PROMOTER, AGENT FOR COMBINATION USE WITH THERAPEUTIC AGENT FOR LYMPHOCYTE-MEDIATED CANCER THERAPY, AND PROMOTER OF MITOCHONDRIAL FUNCTION OF LYMPHOCYTES
GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (Japan)
NAGASAKI UNIVERSITY (Japan)
UNITED IMMUNITY, CO., LTD. (Japan)
Inventor
Asai, Akira
Ogo, Naohisa
Ikeda, Hiroaki
Muraoka, Daisuke
Dotsu, Yosuke
Harada, Naozumi
Abstract
Provided is a lymphocyte function promoter. The lymphocyte function promoter contains at least one selected from the group consisting of a compound represented by general formula (1), a salt thereof, and a solvate of the same.
A membrane element 100 comprises: a separation membrane 10 that removes impurities included in raw water supplied from a supply surface 20a side; and a cylindrical porous membrane 20 that is provided on a permeation surface 10b side opposite to the supply surface 10a side of the separation membrane 10 and removes impurities included in raw water having passed through the separation membrane 10. The cylindrical porous membrane 20 has a plurality of through-holes 20h penetrating from the supply surface 20a toward the permeation surface 20b. The diameters of the through-holes 20h are identical or approximately identical.
B01D 69/00 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
23.
LIPID COMPOUND, LIPOSOME, EXOSOME, LIPID NANOPARTICLE AND DRUG DELIVERY SYSTEM
The present invention addresses the problem of providing a technology for improving the cell-binding properties of a liposome, an exosome or a lipid nanoparticle, and provides a lipid compound having a group represented by general formula (1). (1): XaXb-(X1pp(X2qq-(X3X4rss-
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 43/00 - Drugs for specific purposes, not provided for in groups
B01J 13/02 - Making microcapsules or microballoons
C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
Inventor
Nakagaki Takehiro
Nishida Noriyuki
Satoh Katsuya
Goto Masahiro
Kozaka Shuto
Abstract
This transdermal absorption-type patch is provided with a support and an adhesive agent layer laminated on the support. The adhesive agent layer contains: a solid tacrolimus-surfactant composite in which tacrolimus is covered with a surfactant; an oil phase; and an adhesive agent. The solid tacrolimus-surfactant composite forms solid-in-oil type particles dispersed in the oil phase, and is used for the therapy of neurodegenerative disorders.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 9/66 - Sustained or differential release type containing emulsions, dispersions or solutions
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
25.
PROPHYLACTIC OR THERAPEUTIC AGENT FOR RNA VIRUS-RELATED DISEASES
A a prophylactic or therapeutic agent for RNA virus-related diseases is provided, the prophylactic or therapeutic agent containing, as an active ingredient, at least one compound selected from the group consisting of a selective estrogen receptor modulator, an anti-tuberculosis drug, a CysLT1 receptor antagonist, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, an arachidonate 5-lipoxygenase (5-LOX) inhibitor, a derivative thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable solvate thereof.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
The present invention provides: a three-dimensional hepatocyte cultured product characterized by including hepatocytes and cells reprogramed from hepatocytes and by having a cyst-like structure; and a method for producing a three-dimensional hepatocyte cultured product characterized by culturing hepatocytes or a mixture of hepatocytes and stromal cells by using a culture medium containing a hepatocyte reprogramming substance.
The present invention provides a novel and effective cancer immunotherapeutic agent exhibiting a therapeutic effect against refractory cancers, particularly against cancers for which immune checkpoint inhibitors used as a monotherapy or in combination with another drug are ineffective. Specifically, the present invention provides a cancer treatment agent obtained by combining an immune checkpoint inhibitor, interleukin-18 (IL-18), and a T-cell growth factor (e.g., interleukin-2 (IL-2)).
The compound of one aspect of the present invention is represented by formula (1). R1represents an aryl group that has one or more alkoxy groups, when the aryl group has two or more alkoxy groups, it being possible for at least two of the two or more alkoxy groups to be bonded to each other, R2and R4each independently represent a substituted or unsubstituted aryl group, R3and R5each independently represent a substituted or unsubstituted chain hydrocarbon group, a substituted or unsubstituted styryl group, or a fluorine atom, R6and R7each independently represent a hydrogen atom or a substituted or unsubstituted chain hydrocarbon group, X1and X2each independently represent a fluorine atom or a group represented by -OR8, and R8 represents an alcohol residue or a sugar residue.
The present invention relates to: a compound, or a pharmaceutically acceptable salt thereof, that has an antimalarial action and that is useful as an agent for treating or preventing malaria; and a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, ring A is a benzene ring or the like, R1is a substituted or an unsubstituted alkyl or the like, R2is a halogen or the like, n is an integer between 0 and 4, R3is a substituted or an unsubstituted alkyl, R4is a substituted or an unsubstituted alkyloxy, and R5 is a hydrogen atom or the like.)
C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Provided are a compound and an antiparasitic agent that have an antiparasitic activity against zoonotic parasites consisting of protozoa and helminths and are useful for treating or preventing parasitic infections. This antiparasitic agent comprises a compound represented by general formula (I) or a salt thereof [in the formula: Ar1represents an optionally substituted nitrogen-containing heteroaromatic ring group; X represents a hydroxyl group, an amino group or -NR1R21-61-31-3 alkylene group optionally containing an intervening oxygen or sulfur atom; and Ar2 represents an optionally substituted aryl group or an optionally substituted heteroaryl group].
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
31.
BIOADHESIVE SHEET-SHAPED MATERIAL FOR ATTACHING ONTO SURFACE OF ORGAN
A bioadhesive sheet-shaped material configured to be attached onto a surface of an organ, a method for producing the bioadhesive sheet-shaped material, and a method for treating a disease by using the bioadhesive sheet-shaped material. The bioadhesive sheet-shaped material includes an extracellular matrix layer, a sheet-shaped cell culture, and a biodegradable gel layer, where the sheet-shaped cell culture is interposed between the extracellular matrix layer and the biodegradable gel layer, and the bioadhesive sheet-shaped material is by attaching the extracellular matrix layer onto a surface of an organ.
A vaccine composition for transpulmonary or transnasal administration contains a nucleic-acid-containing carrier having such a structure that a complex comprising a nucleic acid encoding an antigen protein and a cationic molecule is coated with γ-polyglutamic acid or a salt thereof. In the vaccine composition for transpulmonary or transnasal administration, the charge ratio among the nucleic acid, the cationic molecule, and the γ-polyglutamic acid or the salt thereof may be 1:(2 to 8 inclusive):(4 to 16 inclusive). The cationic molecule may be 1,2-dioleoyl-3-trimethylammoniumpropane.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The present invention realizes simple three-dimensional display by providing a region in which diffused lights from adjacent projection devices overlap one another in the reachable range of the diffused lights. The present invention comprises: a retroreflective diffusion screen 12 that is provided with a retroreflective material 13 and a transmissive diffusion layer 14; and three or more projection devices 20 that project images on the retroreflective diffusion screen 12. The images projected from the adjacent projection devices 20 are projected so as to be mutually diffused in the state of overlapping one another. The images reflected on the retroreflective diffusion screen are observed from positions behind the projection devices 20.
G02B 30/35 - Stereoscopes providing a stereoscopic pair of separated images corresponding to parallactically displaced views of the same object, e.g. 3D slide viewers using reflective optical elements in the optical path between the images and the observer
G03B 21/00 - Projectors or projection-type viewers; Accessories therefor
G03B 21/60 - Projection screens characterised by the nature of the surface
H04N 13/351 - Multi-view displays for displaying three or more geometrical viewpoints without viewer tracking for displaying simultaneously
H04N 13/363 - Image reproducers using image projection screens
34.
METHOD FOR PRODUCING SCLEROTOME CELLS AND UTILIZATION OF SAID SCLEROTOME CELLS
The present invention provides a method for producing sclerotome cells from pluripotent stem cells in a xeno-free and feeder-free culture system. This method comprises: (1) a step for culturing pluripotent stem cells in a first differentiation culture medium that contains only a Wnt signal activation agent as an induction factor; (2) a step for switching the cells cultured in step (1) into a second differentiation culture medium that contains only a Wnt signal activation agent, TGFβ signal inhibitor, and BMP signal inhibitor as induction factors, and culturing; (3) a step for switching the cells cultured in step (2) into a third differentiation culture medium containing only a Wnt signal inhibitor, TGFβ signal inhibitor, and BMP signal inhibitor as induction factors, and culturing; and (4) a step for switching the cells cultured in step (3) into a fourth differentiation culture medium containing, as induction factors, only a hedgehog signal activation agent and at least one selection from the group consisting of BMP signal inhibitors and Wnt signal inhibitors, and culturing.
The present invention provides an agent for treating or preventing Chagas disease, characterized by containing one or more compounds selected from the group consisting of coptisin, berberine, palmatine, epiberberine, berberrubine, and ditetrahydrocoptisin, or a salt thereof, or a compound represented by general formula (I) or a salt thereof.
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
36.
NOVEL HUMAN INTERLEUKIN-18 VARIANT AND USE THEREFOR
FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE (Japan)
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY (Japan)
Inventor
Tanaka Yoshimasa
Sakuraba Shun
Abstract
The present invention pertains to a novel interleukin-18 (IL-18) variant and a pharmaceutical composition using the same. Specifically, the present invention pertains to a human IL-18 variant that includes, in the amino acid sequence of wild-type human IL-18, (i) a mutation of the cysteine at positions 38, 68, 76, and 127 into serine, and (ii) a mutation of the glutamic acid at position 6 and the lysine at position 53 into alanine, said human IL-18 variant including (iii) at least 1 additional mutation. The present invention also pertains to a pharmaceutical composition including said human IL-18 variant.
The purpose of the present invention is to provide a means for preventing and treating pancreatic fistula. The present invention achieves the foregoing by providing: a sheet-shaped cell culture for covering a cut surface of the pancreas, the cut surface of the pancreas, which includes cut surfaces of pancreatic parenchyma and pancreas ducts, being bonded to the small intestinal wall through the sheet-shaped cell culture in a liquid-tight manner; and a method for preventing or treating pancreatic fistula, and the like, the method including a step for covering the pancreas cut surface, which includes cut surfaces of pancreatic parenchyma and pancreas ducts, with the sheet-shaped cell culture, and a step for bonding the cut surface of the pancreas to the small intestinal wall through the sheet-shaped cell culture in a liquid-tight manner.
Provided is a storage container for storing a cornea specimen in which an endothelium and an epithelium of a cornea can be immersed and stored in different storage solutions. The storage container 1A is provided with a specimen-supporting portion 3A which contains a first cornea exposure portion 31a and a second cornea exposure portion 31b that expose a cornea part 101, the specimen-supporting portion supporting a scleral rim 102 at an outer circumferential side of the first and second cornea exposure portions 31a, 31b; a first chamber 20a to which an endothelium side of the cornea part 101 in the cornea specimen 100 is exposed, the scleral rim 102 of the cornea specimen 100 being supported by the specimen-supporting portion 3A, and the first chamber containing a first storage solution 60a; and a second chamber 20b to which an epithelium side of the cornea part 101 in the cornea specimen 100 is exposed, the scleral rim 102 of the cornea specimen 100 being supported by the specimen-supporting portion, the second chamber being divided from the first chamber 20a by the specimen-supporting portion 3A, and the second chamber containing a second storage solution 60b that differs from the first storage solution 60a, wherein the storage container is configured to prevent the first and second storage solutions 60a, 60b from being circulated between the first and second chambers 20a, 20b.
A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
39.
METHOD FOR MANUFACTURING CELL POPULATION INCLUDING LIVER PRECURSOR CELLS
A method for producing a cell population containing liver progenitor cells, including the steps of
A method for producing a cell population containing liver progenitor cells, including the steps of
(1) preparing a culture substratum containing a cell population comprising liver progenitor cells and fibroblasts,
(2) physically removing the fibroblast colony from the culture substratum,
(3) detaching cells from the culture substratum, and recovering the detached cells, and
(4) culturing the cells recovered in the step (3) on a collagen-coated culture substratum, and recovering the cells not adhered to the culture substratum is provided by the present invention.
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (Japan)
KAGOSHIMA UNIVERSITY (Japan)
NAGASAKI UNIVERSITY (Japan)
Inventor
Kohara, Michinori
Yasui, Fumihiko
Yamane, Daisuke
Kohara, Kyoko
Morita, Kouichi
Yasutomi, Yasuhiro
Ishii, Koji
Abstract
The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.
Provided is a composition having a cell-derived physiological activity. The osteogenic composition according to the present invention contains a processed product of megakaryocytes or a culture thereof.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A cultured tissue, comprising: glandular cells; glandular cavities formed from the glandular cells; and ducts formed from epithelial cells, wherein the glandular cavities and the ducts are functionally connected ex vivo.
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
43.
METHOD OF PREDICTING ANTICANCER DRUG RESISTANCE AND PROGNOSIS IN KIDNEY CANCER PATIENT, METHOD OF SCREENING ANTI-KIDNEY CANCER SUBSTANCE, AND PHARMACEUTICAL COMPOSITION FOR TREATING KIDNEY CANCER
The present invention provides: a method of predicting the anticancer drug resistance and/or prognosis in a kidney cancer patient, said method comprising a step for evaluating the expression of Largen in the kidney cancer tissue of a subject and a step for comparing the Largen expression level in the kidney cancer tissue of the subject with a control; and a method of screening an anti-kidney cancer substance, said method comprising (1) a step for contacting a test substance with kidney cancer cells that express Largen, (2) a step for measuring the expression amount of Largen in the kidney cancer cells, and (3) a step for comparing the thus determined expression amount of Largen with the expression amount of Largen in the kidney cancer cells that have not been contacted with the test substance and thus selecting a test substance that lowers the expression amount.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 15/00 - Drugs for genital or sexual disorders; Contraceptives
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A method for producing a disease model, including a step of introducing a cancer cell or fibroblast into a recellularized organ or tissue is provided by the present invention.
Foundation for Biomedical Research and Innovation at Kobe (Japan)
Inventor
Tanaka, Yoshimasa
Senju, Hiroaki
Mukae, Hiroshi
Fukushima, Masanori
Abstract
A method may predict risk of onset of severe interstitial pneumonia caused by an immune checkpoint inhibitor to achieve a safe and highly effective cancer immunotherapy. Any one or more selected from: (a) cell count or proportion of Vδ2+γδ T cells in peripheral blood mononuclear cells isolated from a subject; (b) cell count or proportion of Vδ2+γδ T cells after antigenic stimulation in peripheral blood mononuclear cells isolated from a subject; (c) cell count or proportion of Vδ2+γδ T cells in peripheral blood T cells isolated from a subject; and (d) cell count or proportion of Vδ2+γδ T cells after antigenic stimulation in peripheral blood T cells isolated from a subject are measured, and the risk of onset of severe interstitial pneumonia is predicted by using the cell count or proportion as an index.
The present invention provides a saliva collecting container which is simple to use and with which the amount of collected saliva can be easily checked. The present invention includes a container part 1 which has a closed bottom portion 2 and an open top portion 3, wherein: the open top portion 3 is connected, on the lower side thereof, to the closed bottom portion 2 via a first sloped portion 5, which is gently sloped in a funnel form, and a second sloped portion 6, which is continuous with the first sloped portion 5 and which is steeply sloped; and a first hollow portion 7 having a substantially U-shaped cross section is formed to be surrounded by the second sloped portion 6 and the closed portion 2.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
G01N 1/00 - Sampling; Preparing specimens for investigation
G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
The present invention provides a technology that enables rapid detection of SARS-CoV-2 by specifically amplifying nucleic acids originating from SARS-CoV-2. More specifically, the present invention provides a technology related to a primer set and the use of said primer set, the primer set being a SARS-CoV-2 detection primer set that contains a plurality of LAMP primers targeting at least one open reading frame (ORF) region in the SARS-CoV-2 genome, wherein the at least one ORF region is selected from the group consisting of Orf1b, OrfM, OrfN, and OrfS.
This prophylactic or therapeutic agent for RNA virus-related diseases contains, as an active ingredient, at least one compound selected from the group consisting of a selective estrogen receptor modulator, an anti-tuberculous drug, a CysLT1 receptor antagonist, a peroxisom proliferator-activated receptor γ (PPARγ) agonist, an arachidonate 5-lipoxygenase (5-LOX) inhibitor, a derivative thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable solvate thereof.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
49.
CANCER THERAPEUTIC AGENT AND CANCER THERAPEUTIC METHOD
Provided is a cancer therapeutic agent comprising: a hydrophobic anti-cancer agent in an effective amount; a cationic liposome in which the hydrophobic anti-cancer agent is encapsulated; and γ-polyglutamic acid in which the cationic liposome is encapsulated, or a salt thereof, wherein the cationic liposome contains a phospholipid or a salt thereof and contains a cationic lipid or a salt thereof.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
The present invention provides: a therapeutic and/or preventive agent for coronavirus disease 2019 (COVID-19) that contains 5-aminolevulinic acid (ALA), a derivative thereof or a salt of the same; and a method for treating and/or preventing COVID-19 by using the therapeutic and/or preventive agent.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
A device for efficiently attaching a sheet-shaped object to a target site includes a support body for supporting a sheet-shaped object, and a protective member having a low coefficient of friction for protecting one surface of the support, in which the support body supporting the sheet-shaped object is rolled while being protected by the protective member and can be inserted into a tubular body.
A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
Provided is a low cost puncture aid that enables an operator to easily fix a port and to observe the position of a septum, which corresponds to a puncture site. A puncture aid 100 is designed for a catheter access port and assists in puncturing a subcutaneously implanted port 300 of a subcutaneously implanted catheter access port with a Huber needle. The puncture aid 100 is provided with an annular member 110 having a lower surface opening 120 and an upper surface opening 130 that are greater than the outer shape of the subcutaneously implanted port 300, and are shaped to enclose the outer shape.
The present invention provides a compound indicated by formula (I) or a salt thereof that is useful for the prevention or treatment of malaria (in the formula, each of the symbols is as defined in the specification).
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A cover 20 for covering a circumferential portion of an outer circumferential surface of a rigid endoscope 10 having an observation window portion 14 provided at a tip thereof includes a flexible outer cover member 22 covering the circumferential portion of the circumferential surface of the rigid endoscope 10 and a tubular member 26, provided inside the outer cover member 22, through which a cleaning fluid to be supplied from a base end of the rigid endoscope 10 to the observation window portion 14 of the rigid endoscope 10 flows inside, and the outer cover member 22 is attached to the outer circumference surface of the rigid endoscope 10 by flexing the outer cover member 22.
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with cooling or rinsing arrangements
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
55.
BIOADHESIVE SHEET-LIKE MATERIAL FOR ADHESION TO ORGAN SURFACE
The objective of the present invention is to provide a bioadhesive sheet-like material to be used being adhered to an organ surface, a method for manufacturing the same, and a method for treating a disease using the same. The present invention provides a bioadhesive sheet-like material including an extracellular matrix layer, a sheet-like cell culture, and a biodegradable gel layer. The bioadhesive sheet-like material has the extracellular matrix layer on one surface thereof, and the biodegradable gel layer on the other surface thereof via the sheet-like cell culture. Providing, inter alia, the bioadhesive sheet-like material to be used with the extracellular matrix layer adhered to an organ surface solves the above problem.
Provided are a teaching data generation system and a teaching data generation method which enable selection of highly accurate teaching data. This teaching data generation system 1A acquires and stores data having a known accuracy that is used in selection of a teaching data generator, data having an unknown accuracy that becomes a teaching data candidate, a determination result regarding each piece of data, and data about whether the determination result is correct regarding the data having a known accuracy, and then selects the teaching data generator from a determination result made by a teaching data generator candidate regarding the data having a known accuracy that is used in the selection of a teaching data generator, and from the data about whether said determination result regarding the data having a known accuracy is correct. Said teaching data generation system 1A also selects the teaching data from the data having a known accuracy that was used in the selection of the teaching data generator, the data having an unknown accuracy that becomes a teaching data candidate, the determination result regarding each piece of data, and the data about whether the determination result is correct regarding the data having a known accuracy.
The present invention provides: (1) a method for inducing homologous recombination between the genomic DNA of a cell and a donor DNA containing an insertion sequence into the genomic DNA , said method comprising a step for contacting the genomic DNA, the donor DNA and Cas9 nuclease in the absence of guide RNA; and (2) a method for evaluating the possibility of off-target mutagenesis by a nucleic acid for modifying the genomic DNA of a cell, said method comprising a step for calculating the degree of homology between at least a partial sequence of the nucleic acid and at least a partial sequence of the the genomic DNA of the cell, wherein the nucleic acid for modifying the genomic DNA contains one or more nucleotide sequences selected from the group consisting of a nucleotide sequence that encodes a nucleic acid sequence-recognizing module specifically binding to a target nucleotide sequence in the genomic DNA of the cell, a nucleotide sequence that encodes a nucleic acid modifying enzyme, and an insertion sequence into the genomic DNA of the cell.
Provided is a compound having a tyrosine kinase inhibitory activity specific to C797S resistant mutant EGFR (particularly C797S tertiary-resistant mutant EGFR) and is useful as a C797S resistant mutant EGFR (particularly C797S mutant tertiary-resistant EGFR) specific tyrosine kinase inhibitor, an agent for preventing and/or treating non-small cell lung cancer with resistance mutant EGFR and the like, and the like.
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
59.
COVER FOR RIGID ENDOSCOPE, ENDOSCOPE UNIT, AND USE METHOD FOR ENDOSCOPE UNIT
This cover (20) for covering part of the outer circumferential surface in the circumferential direction of a rigid endoscope (10) having an observation window (14) provided to the tip thereof is provided with a flexible cover member (22) that covers part of the outer circumferential surface of the rigid endoscope (10) in the circumferential direction. The cover member (22) has formed therein a plurality of through holes (24, 25) inside of which a gas and a cleaning liquid to be supplied to the observation window (14) of the rigid endoscope (10) from the base end side of the rigid endoscope (10) each flow. The cover member (22) bends and is thereby attached to the outer circumferential surface of the rigid endoscope (10).
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with cooling or rinsing arrangements
This ventilation fan enables an increase in airflow rate without an increase in the size of a casing. The ventilation fan includes: a composite fan 10 comprising first and second ventilation fans 10A, 10B which are connected onto the same rotating shaft 14; a box-shaped casing 20 accommodating the composite fan; a bell mouth 22 for sucking in air, formed through one surface of the casing; and a discharge port 24 provided in one side surface of the casing. The configuration is such that air that has been sucked into the casing, including an airflow that has stagnated inside the casing on the opposite side to the discharge port, is discharged from the discharge port by means of the rotation of the first and second ventilation fans.
F04D 17/04 - Radial-flow pumps specially adapted for elastic fluids, e.g. centrifugal pumps; Helico-centrifugal pumps specially adapted for elastic fluids having non-centrifugal stages, e.g. centripetal of transverse-flow type
F04D 29/28 - Rotors specially adapted for elastic fluids for centrifugal or helico-centrifugal pumps
A storage container is provided for storing a cornea specimen, wherein the endothelium and the epithelium of the cornea can be immersed and stored in different storage liquids. The storage container 1A comprises: a specimen support part 3A that has a first cornea exposure part 31a and a second cornea exposure part 31b that expose a cornea part 101, a sclera outer edge part 102 being supported on the outer peripheral sides of the first cornea exposure part 31A and the second cornea exposure part 31B; a first chamber 20a in which is exposed the endothelial side of the cornea part 101 of the cornea specimen 100 in which the sclera outer edge part 102 is supported by the specimen support part 3A, a first storage liquid 60a being contained in the first chamber 20a; and a second chamber 20b that is demarcated from the first chamber 20a by the specimen support part 3A, the epithelial side of the cornea part 101 of the cornea specimen 100 that is supported by the specimen support part 3A being exposed in the second chamber 20b, and a second storage liquid 60b that differs from the first storage liquid 60a being contained in the second chamber 20b, the storage container 1A being configured so that the first storage liquid 60a and the second storage liquid 60b do not circulate between the first chamber 20a and the second chamber 20b.
The present invention provides a method in which the susceptibility of a subject to the onset of normal-pressure hydrocephalus is tested by detecting the presence or absence of decreased-function mutations in the CFAP43 gene in DNA in a sample from the subject, and comparing against a standard wherein one is susceptible to the onset of normal-pressure hydrocephalus if there is a decreased-function mutation in the CFAP43 gene, and one is not susceptible to the onset of normal-pressure hydrocephalus if there is not a decreased-function mutation in the CFAP43 gene.
Provided is an impeller for an undershot water wheel with which output can be improved on a high tip speed ratio side in comparison to a prior-art undershot water wheel. An impeller 20 for an undershot water wheel comprises: a rotational solid 24 attached to a rotating shaft 22 extending in a direction intersecting the flow of a water channel 80; a plurality of main vanes 26a, 26b, 26c, 26d, 26e, 26f, 26g, 26h provided at prescribed intervals in a peripheral direction around the peripheral edge of the rotational solid 24; and a plurality of auxiliary vanes 28a, 28b, 28c, 28d, 28e, 28f, 28g, 28h provided at prescribed intervals in the peripheral direction, nearer to the rotating shaft 22 than the main vanes 26a, etc., of the rotational solid 24. The main vanes 26a, etc., and the auxiliary vanes 28a, etc., are configured from flat plates.
A cultured tissue containing glandular cells, a glandular lumen formed from glandular cells, and a duct formed from epithelial cells, wherein the glandular lumen and the duct are functionally connected to each other in vitro.
The present invention provides a method for manufacturing a cell population including liver precursor cells, the method comprising (1) a step for preparing a culture base which includes a cell population including liver precursor cells and fibroblasts, (2) a step for physically removing the colony of fibroblasts from the culture base, (3) a step for removing the cells from the culture base and collecting the removed cells, and (4) a step for culturing the cells collected in step (3) in a collagen-coated culture base and collecting cells which have not become adhered to the culture base.
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (Japan)
KAGOSHIMA UNIVERSITY (Japan)
NAGASAKI UNIVERSITY (Japan)
Inventor
Kohara, Michinori
Yasui, Fumihiko
Yamane, Daisuke
Kohara, Kyoko
Morita, Kouichi
Yasutomi, Yasuhiro
Ishii, Koji
Abstract
The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.
The present invention provides a method for producing a disease model, the method including a step for introducing cancer cells or fibroblasts into recellularized organs or tissue.
The objective of the present invention is to provide a device for efficiently attaching a sheet-shaped object onto a target site. The present invention relates to the sheet-shaped object attaching device containing a support for supporting the sheet-shaped object, and a low frictional coefficient protective member for protecting one surface of the support, the device allowing the support supporting the sheet-shaped object to be rolled while being protected by the protective member and inserted into the interior of a cylindrical body.
Provided is an expression inhibitor capable of inhibiting the expression of a fibrosis-inducing gene. The expression inhibitor according to the present invention comprises a compound represented by formula (I) or a salt thereof.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE (Japan)
Inventor
Tanaka Yoshimasa
Senju Hiroaki
Mukae Hiroshi
Fukushima Masanori
Abstract
The purpose of the present invention is to provide a method for predicting the risk of development of severe interstitial pneumonia induced by an immune checkpoint inhibitor, and to achieve a safe and highly effective cancer immunotherapy. At least one of (a) the number or content ratio of Vδ2+γδT cells in peripheral blood mononuclear cells isolated from a subject, (b) the number or content ratio of antigen-stimulated Vδ2+γδT cells in the peripheral blood mononuclear cells isolated from the subject, (c) the number or content ratio of Vδ2+γδT cells in peripheral blood T cells isolated from the subject and (d) the number or content ratio of antigen-stimulated Vδ2+γδT cells in the peripheral blood T cells isolated from the subject is measured, and the risk of development of severe interstitial pneumonia is predicted by employing, as a measure, the number or content ratio.
The purpose of the invention is to provide a compound which has the effect of suppressing abnormal prion production and is useful as a therapeutic agent for prion diseases. Provided are a compound represented by formula (I) (the symbols in the formula are described in the description) or a salt thereof, and a therapeutic agent for prion diseases, the therapeutic agent containing the compound as an active ingredient.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 25/00 - Drugs for disorders of the nervous system
C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The purpose of the present invention is to provide a device for efficiently attaching a sheet-like material onto a target location. This sheet-like material attaching device includes a sheet support body that has a shaft part and a support part for supporting a sheet-like material provided at the distal end of the shaft part. The support part has a plurality of holes and is configured so that the sheet-like material can be peeled and released in the vicinity of a target location inside a body cavity with a fluid discharged from the holes, and the discharge positions for the fluid can be selected to gradually peel the sheet-like material.
The problem to be solved by the present invention is to provide a method of producing isoprenoids including ascofuranone, ilicicolin A, and ascochlorin and derivatives thereof in a high yield as compared to the conventional art, which method enables industrial-scale production of isoprenoids. The problem can be solved by a method of producing isoprenoids such as ascofuranone, ilicicolin A, and ascochlorin, including using a transformant obtained by transformation with biosynthetic genes for ascofuranone, ilicicolin A, or ascochlorin or a knockout organism for these genes to obtain isoprenoids such as ascofuranone, ilicicolin A, and ascochlorin.
Provided in the present specification are: a sheet-like cell-cultured product for promoting healing of a hollow organ having a damaged area, in particular, tissues of duodenum; a method for producing the sheet-like cell-cultured product; a method for regenerating the damaged area of a hollow organ by using the sheet-like cell-cultured product; and the like.
A cover 20, for covering a circumferential portion of the outer peripheral surface of a rigid endoscope 10 provided with an observation window part 14 at a tip thereof, is provided with: a flexible outer cover member 22 which covers the circumferential portion of the outer peripheral surface of the rigid endoscope 10; and a tubular member 26 which is provided inside the outer cover member 22 and into which a cleaning fluid to be supplied from the proximal end side of the rigid endoscope 10 to the observation window part 14 of the rigid endoscope 10 flows, wherein as the outer cover member 22 is bent, the outer cover member 22 is installed on the outer peripheral surface of the rigid endoscope 10.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 1/012 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor characterised by internal passages or accessories therefor
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with cooling or rinsing arrangements
G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes
76.
BIOMARKER FOR DIFFERENTIATING BETWEEN STILL'S DISEASE AND SEPTICEMIA
The present invention provides a biomarker for differentiating between Still's disease and septicemia, comprising any of (a) through (d) below: (a) an FGF-2 protein or an FGF-2 transcription product, (b) an IL-18 protein or an IL-18 transcription product, (c) a G-CSF protein or a G-CSF transcription product, and (d) a GM-CSF protein or a GM-CSF transcription product.
[Problem] To enable an onboard computing device installed in a vehicle to be used in data processing when the vehicle is in a parking lot or the like and not in the process of traveling. [Solution] An onboard computing device 2 installed in a vehicle 1 is equipped with a detection means 13, a dynamically reconfigurable circuit 21, and a switching means 23. The detection means 13 detects whether the vehicle 1 is traveling. The dynamically reconfigurable circuit 21 is capable of carrying out vehicle-travel information processing, which is for assisting the travel of the vehicle 1, when the vehicle 1 is traveling, and is capable of carrying out non-vehicle-travel information processing, which is processing other than the vehicle-travel information processing, when the vehicle 1 is not traveling. The switching means 23 switches the dynamically reconfigurable circuit 21 to a circuit suitable for vehicle-travel information processing when the detection means 13 detects that the vehicle 1 is traveling, and switches the dynamically reconfigurable circuit 21 to a circuit suitable for non-vehicle-travel information processing when the detection means 13 detects that the vehicle 1 is not traveling.
G06F 9/50 - Allocation of resources, e.g. of the central processing unit [CPU]
B60R 16/02 - Electric or fluid circuits specially adapted for vehicles and not otherwise provided for; Arrangement of elements of electric or fluid circuits specially adapted for vehicles and not otherwise provided for electric
78.
DIFFERENTIATION INDUCTION TECHNIQUE USING ACTIN POLYMERIZATION INHIBITOR WHICH IS AIMED AT PRODUCTION OF OSTEOBLAST FROM HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELL
The present invention relates to the highly efficient differentiation of an osteoblast from a stem cell capable of being differentiated into an osteoblast. The present invention provides an osteoblast differentiation promoter comprising an actin polymerization-inhibiting substance.
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
C12Q 1/42 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
The purpose of the present invention is to provide a compound having high binding specificity for amyloid proteins and high blood-brain barrier permeability, and featuring rapid elimination from normal tissues. The present invention relates to: a radionuclide-labeled compound represented by formula (I) (the symbols in the formula are as defined in the description) or a pharmaceutically acceptable salt thereof; and a composition for the diagnosis of amyloid-related disease comprising the same.
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 25/00 - Drugs for disorders of the nervous system
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
[Problem] To provide a capacitor which uses an element other than lithium and has a specific capacity that is equivalent to or more than the specific capacity of a lithium ion capacitor. [Solution] A magnesium ion capacitor 10 according to the present invention is provided with: an electrolyte 40 which is obtained by dissolving a metal salt, wherein magnesium ions and anions are bonded to each other, in an organic solvent; a positive electrode 20 which is formed from a carbon material and is provided with a pore having a size that enables adsorption and desorption of desolvated magnesium ions; a separator 50; and a negative electrode 30 which is arranged opposite to the positive electrode 20, with the separator being interposed therebetween. The negative electrode 30 may be provided with a pore which has a size that enables adsorption and desorption of desolvated magnesium ions.
METHOD FOR DETERMINING CELLS SUITED TO MAINTENANCE CULTURE/INFECTION EVALUATION OF MALARIA PARASITE, ETC., IN WHICH HEMOCYTE-LIKE CELLS DERIVED FROM IMMORTALIZED ERYTHROCYTE PROGENITOR CELLS ARE USED
Provided that a human hemocyte-like cell group suited to erythrocyte-mediated infectious microorganisms such as viruses, bacteria, protozoa, etc., to be studied can be identified, the cell group can be prepared artificially and provided, and it is considered that the problems of a stable supply of cells for erythrocyte-mediated infectious microorganism culture and the reproducibility of research pertaining to erythrocyte-mediated infectious microorganisms can be improved. The present invention has been contrived in view of the problems of the prior art, the purpose of the present invention being to provide a method for determining a human erythrocyte-like cell group for conducting infectious disease research. The present invention provides a method for determining cells suited to infection by, culture of, and/or evaluation of a desired erythrocyte-mediated infectious microorganism, wherein the method includes allowing the microorganism to infect a mixture of at least two types of cells that have different degrees of differentiation from erythrocyte progenitor cell to denucleated erythrocyte due to the inducement of differentiation of hemocyte progenitor cells into erythroid cells.
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
This cover (220, 320, 420) is designed to circumferentially cover a portion of the outer peripheral face of a rigid endoscope 10 and provided with a flexible outer cover part (222, 322, 422) and an inner cover part (223, 323, 423) that is provided on the inner peripheral face of the outer cover part (222, 322, 422) and demarcates a flow path for a washing fluid to be supplied to an observation window part 14 of the rigid endoscope 10. The outer cover part (222, 322, 422) flexes so that the outer cover part (222, 322, 422) can be attached to the outer peripheral face of the rigid endoscope 10.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with cooling or rinsing arrangements
The present invention provides an antitumor agent containing a substance that specifically recognizes a target region of 12 or more consecutive nucleotides including at least part of the Runx binding sequence TGCGGT nearest the transcription initiation site upstream of the transcription initiation site of a c-Myc gene and inhibits the binding of Runx3 to the Runx binding sequence.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The problem to be solved by the present invention is to provide an isoprenoid production method with which it is possible to produce isoprenoids such as ascofuranone, ilicicolin A, ascochlorin and derivatives thereof in higher yields than conventional techniques, and thereby to enable industrial-scale production of isoprenoids. The problem is solved by a method for producing an isoprenoid such as ascofuranone, ilicicolin A or ascochlorin, the method comprising a step of obtaining an isoprenoid such as ascofuranone, ilicicolin A or ascochlorin using a transformant transformed with a biosynthesis gene for ascofuranone, ilicicolin A or ascochlorin, or a knockout organism thereof.
Provided is a compound which has tyrosine kinase inhibitory activity specific against C797S mutation-type resistant EGFR (particularly, C797S mutation-type tertiary resistant EGFR), and is useful as a C797S mutation-type resistant EGFR (particularly, C797S mutation-type tertiary resistant EGFR)-specific tyrosine kinase inhibitor, a prophylactic and/or therapeutic agent for non-small cell lung cancer or the like having resistant mutant EGFR. The present invention is a compound represented by formula (I) [in the formula, X represents O or NH, R1 and R2 each independently represent a hydrogen atom or an optionally substituted hydrocarbon group, R3 and R4 each independently represent a hydrogen atom, a halogen atom, or an optionally substituted hydrocarbon group, and R5 and R6 each independently represent an optionally substituted hydrocarbon group] (excluding compounds represented by formula (II)) or a salt thereof.
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The purpose of the present invention is to provide a compound which has an anti-RNA virus activity and is useful as an anti-RNA virus drug, particularly an anti-influenza virus drug. The present invention provides a compound represented by formula (I) (wherein each symbol is as defined in the description) or a salt thereof.
C07D 215/12 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07F 9/60 - Quinoline or hydrogenated quinoline ring systems
87.
REAGENT FOR ENHANCING TRANSPARENCY OF BIOLOGICALLY DERIVED MATERIAL
The present invention provides: a reagent for enhancing transparency with which it is possible, in a short time and with a simple procedure, to enhance the transparency of a biologically derived material to an excellent degree of transparency while a lipid membrane is held, and to adjust pH within a specific range; a method for enhancing the transparency of a biologically derived material using said reagent; and a kit for enhancing the transparency of a biologically derived material, said kit including said reagent.
[Problem] To alleviate interference of occlusion checking which is performed by a tongue. [Solution] Provided is an occluding paper holder, comprising an occluding paper sandwiching part 20, a holding part 10, a tongue depressor 41, and coupling parts 30. The occluding paper sandwiching part 20 sandwiches and retains a piece of occluding paper 90 with an upper arm 21 and a lower arm 22 which face each other and are freely openable and closeable. The holding part 10 is connected to one end part of the occluding paper sandwiching part 20. The tongue depressor 41 is disposed separated from the occluding paper sandwiching part so as to thrust a tongue inward. With the coupling parts 30, one end part thereof is connected to an opposite side end part of the occluding paper sandwiching part 20 with respect to the holding part 10, and another end part thereof is connected to the tongue depressor 41.
[Problem] To reduce the capacitance of a smoothing capacitor without causing an increase in pulsation of AC output voltage in a power conditioning system. [Solution] This power conditioning system is provided with multiple cell modules 21, a buffer reactor, an output control device, and a charging circuit control device. Each of the cell modules 21 is equipped with: at least two switches 31 disposed in series between cell terminals; a capacitor 32 disposed in series with the switches 31; a battery 33 disposed in parallel with the capacitor 32; and a charging circuit for controlling charging/discharging of the battery. The multiple cell modules 21 are disposed in series between input terminals of the power conditioning system. The buffer reactor is disposed in series with the cell modules 21. The output control device controls the switches 31 so as to convert a DC current input from the input terminals into an AC current. The charging circuit control device controls charging/discharging of the batteries 33 so as to suppress voltage fluctuations of the capacitors 32.
H02M 7/49 - Combination of the output voltage waveforms of a plurality of converters
H02M 7/48 - Conversion of dc power input into ac power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode
90.
Wideband planar circularly polarized antenna and antenna device
A planar antenna includes a patch conductor formed on a front surface of a dielectric substrate 20 so to be obliquely arranged in relation to an orthogonal axis of the dielectric substrate, the patch conductor having an elliptic shape; a microstrip line 40 for feeding power to a bottom part of the patch conductor; and a ground conductor plate 50 formed on a back surface of the dielectric substrate at a position thereof that is not overlapped with the patch conductor. By forming the patch conductor to be inclined only by θ, circular polarization characteristics in which axial ratio is 3 dB or less are given and the wideband such that the frequency bandwidth in which VSWR characteristics are 2 or less is 2 through 5 GHz and the wideband in UWB High band can be attained. The antenna characteristics in which any radiation directivity on the zenith direction does not depend on the frequency are obtained.
A series of fluorine-containing bisphosphonic acids in which an alkylamine side chain is added, a series of fluorine-containing bisphosphonic acids in which an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom is added, to the carbon atom of P—C(F)—P, and a series of fluorine-containing bisphosphonate derivatives in which the acid moiety thereof is esterified by an alkoxymethyl group such as POM group, n-butanoyloxymethyl (BuOM) group and the like, that is, the fluorine-containing bisphosphonic acid and fluorine-containing bisphosphonate derivative represented by the following formula (I):
wherein each symbol is as defined in the DESCRIPTION, can efficiently induce proliferation of peripheral blood γδ T cells that express Vγ2Vδ2 T cell receptor having superior cytotoxicity against tumor cells and virus infected cells, immunize tumor cells and virus infected cells, and can induce cytotoxicity by γδ T cells.
Provided is a novel radioprotectant that comprises a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient [in formula (I): a ring A represents a fused ring; and R1 represents a hydrogen atom or an alkyl group having 1-6 carbon atoms]. In particular, provided is a radioprotectant that comprises a compound represented by formula (A) or (B) as an active ingredient. The radioprotectant according to the present invention reduces cell damage and cell death caused by radiation exposure and exhibits an effect of protecting immune-related cells.
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
According to one embodiment, there is provided a nucleic acid primer set that amplifies a ZEBOV gene. An F1 sequence includes at least 13 consecutive bases included in SEQ ID NO: 31 or 64. An F2 sequence includes at least 13 bases included in SEQ ID NO: 62 or 63. An F3 sequence includes at least 13 bases included in SEQ ID NO: 29, 36, 38, 55, 56, 57, 58, 59, 60, 61 or 61. A B1c sequence includes at least 13 bases included in SEQ ID NO: 68, 69, 70, 71, 72, 73, 74 or 75. A B2c sequence includes at least 13 bases included in SEQ ID NO: 65 or 66. A B3c sequence includes at least 13 bases included in SEQ ID NO: 34, 67, 82 or 83.
wherein each symbol is as defined in the DESCRIPTION, which has an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom, and the acid moiety is esterified with a POM group, an n-butanoyloxymethyl (BuOM) group and the like, exhibit a superior direct or indirect cytotoxicity effect on tumor cells and virus infected cells.
C07F 9/60 - Quinoline or hydrogenated quinoline ring systems
C07F 9/6524 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention aims to provide a pharmaceutical agent for the prophylaxis and/or treatment of Alzheimer's disease, which has a novel action mechanism and shows less side effects. A polyphenol derivative having liposolubility enhanced by the introduction of at least one kind of a liposoluble group selected from the group consisting of a chain saturated hydrocarbon group, a chain unsaturated hydrocarbon group, a cyclic saturated hydrocarbon group, a cyclic unsaturated hydrocarbon group, an aromatic hydrocarbon group, a liposoluble vitamin residue and a sterol residue has an action to potentiate neprilysin activity, and is useful as a pharmaceutical agent for the prophylaxis and/or treatment of Alzheimer's disease.
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
To reduce the risk of damaging organs in a body while delivering a thread during surgery, an instrument for delivering a surgical thread has a grip, an outer cylinder fixed the grip, a hollow needle extending inside the outer cylinder and being configured to be moved relative to the outer cylinder in an axial direction and a loop configured to be housed in the outer cylinder. An end of the outer cylinder is bent in a state where force is not applied. The hollow needle is exposed from the outer cylinder when puncturing skin or etc., and the hollow needle is housed in the outer cylinder when it travels near organs which should not be damaged.
A61B 17/04 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for suturing wounds; Holders or packages for needles or suture materials
A61B 17/06 - Needles; Holders or packages for needles or suture materials
A61B 17/12 - Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets
NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (Japan)
NAGASAKI UNIVERSITY (Japan)
KOGAKUIN UNIVERSITY (Japan)
GINKYO GAKUEN (Japan)
TOKYO METROPOLITAN GOVERNMENT (Japan)
SCHOOL JUDICIAL PERSON IKUTOKUGAKUEN (Japan)
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japan)
SHIZUOKA PREFECTURAL UNIVERSITY CORPORATION (Japan)
Inventor
Masutani, Mitsuko
Sakuma, Hiroaki
Sasaki, Yuka
Koizumi, Fumiaki
Kodera, Yasuo
Sasaki, Takayuki
Shimoyama, Tatsu
Inoue, Kengo
Matsuno, Kenji
Okawara, Tadashi
Islam, Rafiqul
Takamura, Takeji
Irie, Tetsumi
Ishikawa, Yoshinobu
Abstract
Provided is a polyaromatic compound or a pharmacologically acceptable salt thereof, said polyaromatic compound being expressed by formula (I) (therein, A is a biaryl to which a substituted or unsubstituted monocyclic aromatic ring has been bonded, B is a nitrogen-containing monocyclic aromatic ring, C is substituted or unsubstituted benzene, D is substituted or unsubstituted pyrimidine, X is a carbonyl group, Z is NH, and R1 is one substance selected from the group consisting of hydrogen, halogens, substituted or unsubstituted linear or branching C1-6 alkyl groups, substituted or unsubstituted linear or branching C2-6 alkenyl groups, substituted or unsubstituted linear or branching C2-6 alkynyl groups, substituted or unsubstituted C3-6 cycloalkyl groups, organic oxy groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heteroaryl groups, substituted or unsubstituted heterocycloalkyl groups, substituted or unsubstituted aralkyl groups, and substituted or unsubstituted heteroarylalkyl groups). By using the compound of formula (I), the present invention also provides a poly (ADP-ribose) glycohydrolase (PARG) inhibitor, a poly (ADP-ribose) (PAR) accumulation promoter, a cell proliferation inhibitor, a proliferative disease therapeutic agent such as an anticancer agent or similar, an effect enhancer for an anticancer agent, a radiation sensitizing action agent, knockdown cells for use in screening for PARG inhibitors, and a method for determining the efficacy of cancer therapy in a biological sample taken from a subject to whom a PARG inhibitor has been prescribed.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 9/99 - Enzyme inactivation by chemical treatment
The present invention provides a therapeutic agent for sarcopenia or metabolic diseases, which contains a mu-crystalline (CRYM)-inhibiting substance as an active ingredient. The inhibiting substance is selected from the group consisting of an antisense nucleic acid for CRYM, an RNAi-induced nucleic acid, a ribozyme or an expression vector therefore, an antagonist antibody, and a low-molecular-weight compound capable of inhibiting the activity of CRYM.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
[Problem] To provide a power conversion circuit control device with which, upon transition of control from normal mode to current limit mode, an output current or output voltage can rapidly converge to a predetermined value without causing vibrations in the output current or output voltage. [Solution] A control device 1 is provided with: an overcurrent detection unit 11 which detects an output current io exceeding a limit value; a first control unit 12 which generates a control signal in normal mode; a second control unit 13 which generates a control signal in current limit mode; and a control signal selection unit which selects the control signal generated by the first control unit 12 or the control signal generated by the second control unit 13. The first control unit generates the control signal in normal mode on the basis of a dynamic characteristics arithmetic expression which includes an output voltage of a power conversion circuit 4 and which is dependent on time. The second control unit generates the control signal in current limit mode by detecting a load resistance and on the basis of a static characteristics arithmetic expression which includes a resistance value and an output current preset value and which is not dependent on time.
H02M 3/155 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only
H02M 3/28 - Conversion of dc power input into dc power output with intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate ac
patents
